Literature DB >> 3440247

Amelioration of adriamycin toxicity through modification of drug-DNA binding properties.

M Israel1, R Seshadri, Y Koseki, T W Sweatman, J M Idriss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3440247     DOI： 10.1016/0305-7372(87)90003-x

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  5 in total

1.  Comparative uptake and retention of adriamycin and N-benzyladriamycin-14-valerate in human CEM leukemic lymphocyte cell cultures.

Authors:  M Israel; T W Sweatman; R Seshadri; Y Koseki
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Growth inhibition of human Tenon's capsule fibroblasts and rabbit dermal fibroblasts with non-carcinogenic N-alkylated anthracyclines.

Authors:  U H Steinhorst; E P Chen; S F Freedman; R Machemer; D L Hatchell
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-06       Impact factor: 3.117

3.  Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat.

Authors:  G Han; M Israel; R Seshadri; J T Dalton; T W Sweatman
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.

Authors:  R Ganapathi; D Grabowski; T W Sweatman; R Seshadri; M Israel
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

5.  Effects of anthracycline derivatives on hepatic neoplastic nodules of Lewis lung carcinoma and colon adenocarcinoma 26.

Authors:  M Iigo; K Nishikata; Y Nakajima; A Hoshi
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.